Prevention of late postmyocardial infarction left ventricular remodeling: an update

Farouk Mookadam1, Sherif E Moustafa

  • 1Department of Cardiovascular Diseases, Mayo College of Medicine, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA. mookadam.farouk@mayo.edu

Insights

Cardiac remodeling is a key target for heart attack and heart failure patients. This review covers current and future therapies aimed at preventing and reversing adverse cardiac remodeling after myocardial infarction (MI).

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Myocardial Infarction Studies

Background:

  • Cardiac remodeling is a critical mechanism driving heart failure progression after myocardial infarction (MI).
  • Increased survival from acute MI necessitates strategies to manage long-term consequences like adverse ventricular remodeling.
  • Left ventricular remodeling serves as a vital surrogate marker for clinical outcomes in heart failure patients.

Purpose of the Study:

  • To review the impact of existing and emerging therapeutic strategies on left ventricular remodeling and dysfunction post-MI.
  • To provide a comprehensive overview of interventions targeting cardiac remodeling.
  • To highlight future directions in preventing and reversing adverse cardiac remodeling.

Main Methods:

  • Literature review of current and experimental therapeutic strategies.
  • Analysis of pharmacotherapy, percutaneous interventions, device-based therapies, and surgical procedures.
  • Synthesis of research on novel approaches to cardiac remodeling.

Main Results:

  • Established therapies including pharmacotherapy and interventions help manage remodeling.
  • Experimental research is yielding novel approaches for remodeling prevention and reversal.
  • Understanding remodeling mechanisms is crucial for improving patient outcomes after MI.

Conclusions:

  • Effective management of cardiac remodeling is essential for improving prognosis in MI survivors.
  • A combination of current and future therapies holds promise for preventing and reversing adverse cardiac remodeling.
  • Continued research into novel therapeutic strategies is vital for advancing heart failure treatment.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...